000169037 001__ 169037
000169037 005__ 20240229133637.0
000169037 0247_ $$2doi$$a10.1111/ced.14773
000169037 0247_ $$2pmid$$apmid:34056759
000169037 0247_ $$2ISSN$$a0307-6938
000169037 0247_ $$2ISSN$$a1365-2230
000169037 037__ $$aDKFZ-2021-01204
000169037 041__ $$aEnglish
000169037 082__ $$a610
000169037 1001_ $$00000-0001-7862-3695$$aGambichler, T.$$b0
000169037 245__ $$aNOD2 signalling in hidradenitis suppurativa.
000169037 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2021
000169037 3367_ $$2DRIVER$$aarticle
000169037 3367_ $$2DataCite$$aOutput Types/Journal article
000169037 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642078508_473
000169037 3367_ $$2BibTeX$$aARTICLE
000169037 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169037 3367_ $$00$$2EndNote$$aJournal Article
000169037 500__ $$a2021 Dec;46(8):1488-1494
000169037 520__ $$aHidradenitis suppurativa (HS) is associated with dysregulated immune responses including altered expression of cytokines, chemokines, and antimicrobial peptides and proteins (AMPs).To evaluate the expression of NOD2 and related factors in HS skin samples and keratinocyte cultures.We performed RT-PCR for NOD2, RIP2, CARL, SKALP/elafin, human ß-defensin 2 (hBD2), LL37, psoriasin, RNAse7 in lesional and non-lesional skin of 19 HS patients and keratinocyte cultures (unstimulated, MDP-stimulated, PAM-stimulated) from and non-lesional skin.We observed significantly elevated mRNA expression for NOD2 (P = 0.0039), hBD2 (P = 0.018), RNase7 (P = 0.0003), psoriasin (P = 0.0053), and SKALP/elafin (P = 0.020) in lesional skin when compared to non-lesional skin. We found a significant correlation between NOD2 mRNA and hBD2 (r = 46; P = 0.039), psoriasin (r = 0.67; P = 0.0016), SKALP/elafin (r = 0.65; P = 0.0026). In unstimulated, PAM-stimulated, and MDP-stimulated normal keratinocytes, NOD2, RIP2, CARL, and SKALP/elafin expression significantly (P < 0.05) increased from 6 h to 48 h. In unstimulated, PAM-stimulated, and MDP-stimulated HS keratinocytes, RIP2, CARL, and SKALP/elafin expression significantly (P < 0.05) declined from 6 h to 48 h. mRNA expression of HS keratinocytes at 6 h was significantly increased for NOD2 (unstimulated, PAM, MDP), CARL (unstimulated, PAM, MDP), and SALP/elafin (unstimulated, PAM) as compared to normal keratinocytes.We have shown for the first time that the NOD2 signalling is activated in HS and might contribute to the pathogenesis via induction of AMPs and activation of other pathways such as NFκB signalling.
000169037 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000169037 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169037 7001_ $$aHessam, S.$$b1
000169037 7001_ $$aSkrygan, M.$$b2
000169037 7001_ $$aBakirtzi, M.$$b3
000169037 7001_ $$0P:(DE-He78)a9aa7740c4c6f243d651d9bd35ed7fdf$$aKasakovski, D.$$b4$$udkfz
000169037 7001_ $$aBechara, F. G.$$b5
000169037 773__ $$0PERI:(DE-600)2004506-2$$a10.1111/ced.14773$$gp. ced.14773$$n8$$p1488-1494$$tClinical and experimental dermatology$$v46$$x1365-2230$$y2021
000169037 909CO $$ooai:inrepo02.dkfz.de:169037$$pVDB
000169037 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9aa7740c4c6f243d651d9bd35ed7fdf$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169037 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000169037 9130_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000169037 9141_ $$y2021
000169037 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-28$$wger
000169037 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-28$$wger
000169037 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EXP DERMATOL : 2019$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000169037 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-28
000169037 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000169037 980__ $$ajournal
000169037 980__ $$aVDB
000169037 980__ $$aI:(DE-He78)A190-20160331
000169037 980__ $$aUNRESTRICTED